Skip to main content
Have a personal or library account? Click to login
Recurrent invasive lobular carcinoma presenting as a ruptured breast implant Cover

Recurrent invasive lobular carcinoma presenting as a ruptured breast implant

Open Access
|Oct 2011

References

  1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010.2010;: 277-300.
  2. Toikkanen S, Pylkkänen L, Joensuu H. Invasive lobular carcinoma of the breast has better short- and long-term survival than invasive ductal carcinoma.1997;: 1234-40.
  3. Harake MD, Maxwell AJ, Sukumar SA. Primary and metastatic lobular carcinoma of the breast.2001;: 621-30.
  4. Winchester DJ, Chang HR, Graves TA, Menck HR, Bland KI, Winchester DP. A comparative analysis of lobular and ductal carcinoma of the breast: presentation, treatment and outcomes.1998;: 416-22.
  5. Ulukaya E, Karaagac E, Ari F, Oral AY, Adim SB, Tokullugil AH, et al. Chemotherapy increases caspase-cleaved cytokeratin 18 in the serum of breast cancer patients.2011;: 116-22.
  6. Plesnicar A, Golicnik M, Fazarinc IK, Kralj B, Kovac V, Plesnicar BK. Attitudes of midwifery students towards teaching breast-self examination.2010;: 52-6.
  7. Pestalozzi B. Portrait of invasive lobular carcinoma of the breast.2009;: 450-1.
  8. Hussien MI, Anwar IF, Down SK, Rizvi S, Farooq N, Burger A, et al. Invasive lobular carcinoma of the breast: should this be regarded as a chronic disease?2010;: 346-52.
  9. Arpino G, Bardou VJ, Clark GM, Elledge RM. Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome.2004;: 149-56.
  10. Sastre-Garau X, Jouve M, Asselain B, Vincent-Salomon A, Beuzeboc P, Dorval T, et al. Infiltrating lobular carcinoma of the breast: clinicopathologic analysis of 975 cases with reference to data on conservative therapy and metastatic patterns.1996;: 113-20.
  11. Pestalozzi BC, Zahrieh D, Mallon E, Gusterson BA, Price KN, Gelber RD, et al. Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 international breast cancer study group clinical trials.2008;: 3006-14.
  12. Dian D, Herold H, Mylonas I, Scholz C, Janni W, Sommer H, et al. Survival analysis between patients with invasive ductal and invasive lobular breast cancer.2009;: 23-8.
  13. Harris M, Howell A, Chrissohou M, Swindell RIC, Hudson M, Sellwood RA. A comparison of the metastatic pattern of infiltrating lobular carcinoma and infiltrating duct carcinoma of the breast.1984;: 23-30.
  14. Borst MJ, Ingold JA. Metastatic patterns of invasive lobular versus invasive ductal carcinoma of the breast.1993;: 637-42.
  15. Lamovec J, Bracko M. Metastatic pattern of infiltrating lobular carcinoma of the breast: an autopsy study.1991;: 28-33.
  16. Harris EER, Santiago RJ, Qin L, Hwang WT, Solin LJ. Similar long-term results of breast-conservation treatment for stage i and ii invasive lobular carcinoma compared with invasive ductal carcinoma of the breast.2005;: 2447-54.
  17. Singletary SE, Patel-Parekh L, Bland KI. Treatment trends in early-stage invasive lobular carcinoma: a report from the National Cancer Data Base.2005;: 281-9.
  18. Katz A, Strom EA, Buchholz TA, Thames HD, Smith CD, Jhingran A, et al. Locoregional recurrence patterns after mastectomy and doxorubicin-based chemotherapy: implications for postoperative irradiation.2000;: 2817-27.
  19. Overgaard M, Jensen MB, Overgaard J, Hansen PS, Rose C, Andersson M, et al. Postoperative radiotherapy in high-risk postmenopausal breast cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82C randomized trial.1999;: 1641-8.
  20. Ragaz J, Jackson SM, Le N, Plenderleith IH, Spinelli JJ, Basco VE, et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer.1997;: 956-62.
  21. Recht A, Gray R, Davidson NE, Fowble BL, Solin LJ, Cummings FJ, et al. Locoregional failure 10 years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation: experience of the Eastern Cooperative Oncology Group.1999;: 1689-700.
  22. Willner J, Kiricuta IC, Kölbl O. Locoregional recurrence of breast cancer following mastectomy: always a fatal event? results of univariate and multivariate analysis.1997;: 853-63.
  23. de Camara DL, Sheridan JM, Kammer BA. Rupture and aging of silicone gel breast implants.1993;: 828-34.
  24. Robinson OG Jr, Bradley EL, Wilson DS. Analysis of explanted silicone implants: a report of 300 patients.1995;: 1-6.
  25. Brinton LA, Brown SL. Breast implants and cancer.1997;: 1341-9.
  26. Silverstein MJ, Handel N, Gamagami P, Gierson ED, Furmanski M, Collins AR, et al. Breast cancer diagnosis and prognosis in women following augmentation with silicone gel-filled prostheses.1992;: 635-640.
  27. Leibman AJ, Kruse B. Breast cancer: mammographic and sonographic findings after augmentation mammoplasty.1990;: 195-8.
  28. Brody GS, Deapen DM. Breast cancer diagnosis is the augmented patient [letter].1989;: 256-8.
  29. Deapen DM, Bernstein L, Brody GS. Are breast implants anticarcinogenic? A 14-year follow-up of the Los Angeles Study.1997;: 1346-53.
  30. Birdsell DC, Jenkins H, Berkel H. Breast cancer diagnosis and survival in women with and without breast implants.1993;: 795-800.
  31. Petit JY, Le MG, Mouriesse H, Rietjens M, Gill P, Contesso G, et al. Can breast reconstruction with gel-filled silicone implants increase the risk of death and second primary cancer in patients treated by mastecomty for breast cancer?1994;: 115-9.
  32. Mátrai Z, Tóth L, Gulyás G, Szabó E, Szentirmay Z, Kásler M. A desmoid tumor associated with a ruptured silicone breast implant.2011;: 1e-4e.
DOI: https://doi.org/10.2478/v10019-011-0032-5 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Language: English
Page range: 23 - 27
Published on: Oct 8, 2011
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2011 Maikel Botros, Kenneth Chang, Robert Miller, Sunil Krishnan, Matthew Iott, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons License.